Advaita Bioinformatics (Advaita) announced today that it has entered into an exclusive partnership with Riken Genesis Co. Ltd., (Riken-Genesis) for the promotion and sale of Advaita’s flagship product, iPathwayGuide in Japan. Under the agreement, iPathwayGuide will be a featured informatics solution for Riken-Genesis’s customers.
With the ever-increasing use of genetic sequencing, the volume of data available for analysis has grown exponentially. Current methods for analyzing these data have been lagging. Advaita’s iPathwayGuide has a unique approach that allows users to quickly identify the mechanisms that may be causing the condition being studied. Advaita’s latest endeavors are targeted toward personalized medicine and leverage a cloud infrastructure to deliver results in minutes instead of weeks or months.
“We are very excited to work with Riken-Genesis on this endeavor. Through our partnership, we will expose the usefulness and advance capabilities of iPathwayGuide to Riken-Genesis’s customers throughout Japan,” said Sorin Draghici, President and CEO, Advaita. “We have already seen incredible interest for our software and this collaboration will provide a dedicated resource for Japanese customers.”
iPathwayGuide takes data from next-generation sequencing and other gene expression experiments and performs an Impact Analysis ™ to identify the gene signaling pathways that are impacted in the given condition. “Through Impact Analysis™, iPathwayGuide considers the type, role, and position of each gene on the pathway, as well as all the gene-gene signals at the system level. This virtually eliminates the false positives that are commonplace with other pathway analysis applications, as well as greatly enhances our ability to find the truly impacted pathways.” explained Advaita’s Vice President, Andrew Olson. iPathwayGuide also performs a number of other analyses including, differential expression, GO analysis, prediction of micro RNAs (miRNAs), diseases, meta-analysis and allows users to model drugs, miRNAs, and SNPs directly on pathways.
iPathwayGuide is a free-to-use web-based application. Users can freely upload and analyze their data without charge. The results of each analysis are available to the user for a period of time to asses their usefulness. If deemed useful, users may purchase unlimited access to the analysis results.
Riken-Genesis was established in 2007 as a RIKEN Venture company to take over the genome analysis resources (human resources, technologies, and facilities) of RIKEN Research Institute, which had been a global driving force in the field of genomic medical science. In the context of rapid advances in research on elucidating the causes of disease at the genetic level and of the side effects of drugs, Riken-Genesis is utilizing its cutting-edge genomics technologies to contribute to the practical implementation of treatment tailored to individual patients (personalized medicine).
Riken-Genesis is a contract genomics analysis service provider able to meet a diverse array of genomic analysis needs. Boasting one of the world’s largest genomics laboratories, the company provides a full range of services to all sorts of research institutions both in Japan and overseas, including pharmaceutical companies, medical institutions, and universities.
Riken-Genesis is also contributing to furthering the use of companion diagnostics and other forms of treatment tailored to individual patients (personalized medicine) through the development, manufacture, and marketing of in vitro diagnostics utilizing advanced genomic technologies. Riken-Genesis is developing, manufacturing and marketing genetic diagnosis test kits, as well as engaging in manufacture and marketing for the domestic introduction of foreign kits for in vitro diagnosis.
Advaita Bioinformatics is a leader in the development of analytic solutions for biological data. Founded in 2005 with headquarters near Ann Arbor, Michigan, Advaita’s novel analysis helps translate the gigabytes of genomic data produced as a result of next-generation sequencing experiments into a better understanding of the underlying biological phenomena. Advaita’s patented approach delivers results and insights that cannot be achieved with any other commercial analysis software. iPathwayGuide is the first web application capable of identifying mechanisms of action, relevant microRNAs, and potential drug targets directly from gene-expression experiments. These unique abilities help researchers quickly zero in on drug targets and validate drug candidates with the greatest potential for success while avoiding costly dead ends. For more information, please go to www.AdvaitaBio.com.